Journal of Neuroinflammation publishes data on Eleva’s lead retinal asset CPV-104

A study published in collaboration with the University of Cologne evaluated the effects of intravitreal injections of CPV-104 on ocular disease processes. Image credit: ©jitendra jadhav – stock.adobe.com

Eleva has published new data on its lead pipeline asset CPV-104, a recombitant variant of human complement factor H. These data will appear in the Journal of Neuroinflammation, a peer-reviewed, open access journal focused on the interactions of the immune system.

In an established animal model of age-related macular degeneration (AMD), Eleva’s recombinant human CPV-104 improved two hallmarks of the disease by statistically significantly dampening the inflammatory activity of microglia and Müller cells in the eye and attenuating light-induced retinal degeneration, the company said in a press release.

About CPV-104

In Eleva's press release regarding the publication announcement, Andreas Schaaf, PhD, chief scientific officer of Eleva, noted that the study findings mark a milestone in the therapeutic candidate’s development. He said, “Our innovative Factor H (CPV-104) programme continues to generate positive data underlining its broad potential in both complement-related rare disorders and larger indications that correlate with complement deregulation like dry AMD. The in vivo data published today bode well for the ongoing expansion of the development program into additional indications branching out from our initial focus on C3 Glomerulopathy (C3G).”

The press release also called out a study published in collaboration with the University of Cologne in Germany, which evaluated the effects of intravitreal injections of CPV-104 on disease processes such as retinal degradation following light exposure and indicators of the inflammatory process, such as microglia morphology, localisation and migration patterns that drive disease progression. The results of this study offer insights into the neuroprotective and immunomodulatory potential of a human CPV-104 treatment, indicating that it may be used to delay or prevent dry AMD disease progression in humans.

The full publication of this study, which is entitled “Moss-derived human complement factor H modulates retinal immune response and attenuates retinal degeneration” is available on the Journal of Neuroinflammation website.

More background on Eleva

Eleva, a clinical-stage biopharmaceutical company, is dedicated to discovering and developing previously inaccessible biologics. The company’s proprietary pipeline includes candidates for complement disorders and enzyme replacement therapies. Factor H, a recombinant human complement and the basis for the therpaeutic CPV-104, is expected to enter clinical studies in C3 Glomerulopathy (C3G) in H1 2025. Dry AMD has been selected as the second indication. The company’s aGal (RPV-001) program to treat Fabry disease has completed a positive Phase 1b clinical trial. All programmes are sourced from Eleva’s transformative moss-based technology platform, which allows lab to GMP-scale manufacturing of previously undruggable human proteins with therapeutic potential.

Reference:

Eleva Publishes Evidence of Immunomodulation and Neuroprotection Using its Factor H Biological Therapy in Preclinical Dry AMD Study. Eleva. April 15, 2025. Accessed April 15, 2025. https://www.biotechnewswire.ai/202504152631/eleva-publishes-evidence-of-immunomodulation-and-neuroprotection-using-its-factor-h-biological-therapy-in-preclinical-dry-amd-study.html